FDA Drug Recalls

Recalls / Class II

Class IID-0430-2024

Product

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Twice-a-Day Dosage, 100 Capsules per bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ, 07430, Product of India, NDC 68462-562-01

Brand name
Diltiazem Hydrochloride
Generic name
Diltiazem Hydrochloride
Active ingredient
Diltiazem Hydrochloride
Route
Oral
NDCs
68462-562, 68462-850, 68462-851
FDA application
ANDA212317
Affected lot / code info
Lot #: 17230304, Exp. 12/31/2024.

Why it was recalled

Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Recalling firm

Firm
Glenmark Pharmaceuticals Inc., USA
Manufacturer
GLENMARK PHARMACEUTICALS INC., USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
750 Corporate Dr, Mahwah, New Jersey 07430-2009

Distribution

Quantity
6,528 bottles
Distribution pattern
Nationwide in the US

Timeline

Recall initiated
2024-03-26
FDA classified
2024-04-02
Posted by FDA
2024-04-10
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0430-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.